Bright Minds Biosciences to join FPWR symposium and PWS family conference in October 2026

Bright Minds Biosciences Inc. announced on September 30, 2026 that it will take part in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, scheduled for October 7-8, and the PWS Family Conference, set for October 9-10, both at the Marriott Philadelphia Downtown. The company describes itself as a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders.¹ More specifically, the company said it is developing highly selective, Gq-biased 5-HT2C agonists designed to restore signaling through this pathway while avoiding the receptor desensitization and 5-HT2B-related cardiac liabilities that limited earlier serotonergic agents.¹

The company's lead PWS candidate, BMB-101, is being tested in a study called NOVA. According to the release, this is a randomized, double-blind, placebo-controlled Phase 2a study assessing the effect of BMB-101 on hyperphagia (primary endpoint: change from baseline in the Hyperphagia Questionnaire for Clinical Trials, HQ-CT), PWS-associated behaviors, and safety and tolerability over a 16-week treatment period, with an optional open-label extension.¹ CEO Ian McDonald said in the release that the NOVA study of BMB-101 is under way.

In a separate corporate update, Bright Minds disclosed that it entered into a mutual rescission and release agreement with an officer of the Company rescinding the officer's prior exercise of stock options in respect of 44,500 common shares, with the shares to be returned to treasury and cancelled, the exercise price refunded, and the options restored on their original terms.¹ The company said no other options are affected.